ORIGINAL ARTICLE. The Long-term Course of Rapid-Cycling Bipolar Disorder

Size: px
Start display at page:

Download "ORIGINAL ARTICLE. The Long-term Course of Rapid-Cycling Bipolar Disorder"

Transcription

1 ORIGINAL ARTICLE The Long-term Course of Rapid-Cycling Bipolar Disorder William Coryell, MD; David Solomon, MD; Carolyn Turvey, PhD; Martin Keller, MD; Andrew C. Leon, PhD; Jean Endicott, PhD; Pamela Schettler, PhD; Lewis Judd, MD; Timothy Mueller, MD Background: Rapid cycling among patients with bipolar affective disorders is important because of its implications for long-term prognosis and for the use of antidepressants. To our knowledge, no prospective study has, as yet, described the course of this phenomenon beyond 5 years. Methods: From 345 patients with bipolar I or bipolar II disorder followed up for a mean (SD) of 13.7 (6.1) years as part of the National Institute of Mental Health Collaborative Depression Study, 89 (25.8%) were identified who, during 1 or more years of follow-up, manifested a pattern that met DSM-IV criteria for rapid cycling. These patients were compared with the remaining bipolar patients by demographics, overall affective morbidity, morbidity during specific treatment conditions, and the likelihood of suicidal behavior. Analyses assessed whether the use of tricyclic antidepressants for depressive symptoms was associated with the persistence of rapid cycling or with tendencies to switch from depressive to manic or hypomanic phases. Results: The 89 patients who showed a rapid cycling pattern were significantly more likely to have had an illness onset before 17 years of age and were more likely to make serious suicide attempts. In 4 of 5 cases, rapid cycling ended within 2 years of its onset. Resolutions were not associated with decreases in tricyclic antidepressant use. Throughout follow-up, patients prone to rapid cycling experienced more depressive morbidity than other bipolar patients, particularly when lithium carbonate was being used without tricyclic antidepressants. The use of these antidepressants was not more likely in the weeks preceding shifts from depression to mania or hypomania. Conclusions: These results indicate that bipolar patients who develop a rapid cycling pattern suffer substantial depressive morbidity and are at high risk for serious suicide attempts. These findings do not implicate tricyclic antidepressants or, by inference, serotonin reuptake inhibitors in the promotion of affective instability. Arch Gen Psychiatry. 2003;60: From the National Institute of Mental Health Collaborative Program on the Psychobiology of Depression Clinical Studies, Bethesda, Md. SEVERAL CONSIDERATIONS give importance to the phenomenon of rapid cycling. 1 In accord with the kindling hypothesis evoked to explain it, rapid cycling may reflect a sensitization produced by repeated episodes. 2,3 If, as suspected, such sensitization is often an enduring change, 3 the prognostic significance of rapid cycling should be long lasting as well. Some follow-up studies have supported this view, 4,5 but others have shown rapid cycling to be time limited. 6 Of perhaps greater concern to clinicians is the suggestion that antidepressants may both trigger and prolong rapid cycling The pattern often begins while antidepressants are being taken, and cycle lengths, the period from the beginning of one episode to the beginning of the next, have been seen to increase after antidepressant treatment was withdrawn. 7,8 These observations may be explained in other ways, however. Some investigators have noted that rapid cycling is likely to begin with depression 8 and that episodes that do begin with depression are substantially more likely to develop a polyphasic 9,10 or rapid cycling 6,11 course than are those that begin with mania. Because all studies of rapid cycling have described patients who sought treatment, those who did so during depressive phases were likely to be receiving antidepressants. Thus, depression may predispose both to antidepressant treatment and, independently, to phase shifting. Data from the National Institute of Mental Health Collaborative Depression Study 12 support this view. A regression analysis showed that the presence of depression preceding study intake, but not exposure to antidepressants, was an independent predictor of rapid cycling in the first year of follow-up. 6 A subsequent regression 914

2 analysis showed that depression during the first year of follow-up, but not antidepressant use in that year, predicted rapid cycling in the second year. 11 The conclusion that the discontinuation of antidepressants promotes the resolution of rapid cycling rests on 2 case series. In the first, 7 21 patients with rapid cycling were persuaded to discontinue antidepressant treatment, and 13 subsequently stabilized. The role of spontaneous stabilization could not be assessed, though, because the authors did not describe the course of patients who continued to take antidepressants. The second study 8 described cycle lengths in 9 rapid cyclers before and after discontinuation of tricyclic antidepressants (TCAs). Cycle lengths were longer during periods without TCAs. Because cycle length is timed from the beginning of one phase to the beginning of the next, it necessarily encompasses any intervening euthymic period. If depression portends further rapid cycling, as previous results have shown, and if antidepressants were more likely to have been discontinued during periods of euthymia than during periods of depression, as might be expected, then the association between antidepressant discontinuation and longer cycle lengths may have been artifactual. The presumption that antidepressants trigger or prolong rapid cycling suggests that patients who experience this phenomenon may be particularly liable to exhibit mania or hypomania while taking antidepressants. This may be especially true for TCAs. These were expressly implicated in the series by Wehr et al 8 and in a meta-analysis of placebo-controlled studies. 13 The latter showed a significantly higher likelihood of switching during TCA treatment than during treatment with selective serotonin reuptake inhibitors (SSRIs). If a liability to rapid cycling is inherent, then other features should distinguish bipolar patients who develop this pattern from those who do not. Of these, female sex has most consistently differentiated rapid cyclers from other bipolar patients. 6,7,14-16 In contrast, bipolar patients with and without rapid cycling have generally not differed by current age or by age at illness onset. However, none of the relevant reports have presented the distributions of the ages at which bipolar illness first appeared. Observations that rapid cycling or, more specifically, continuous cycling is very common among children and early adolescents who have bipolar illness 14,15 suggests 2 possibilities. Either childhood and adolescence have time-limited pathoplastic effects on bipolar illness that then resolve with adulthood, or very-earlyonset bipolar illness carries a liability to rapid cycling that is lifelong. If the latter is true, patients with very early onset should be overrepresented among those who show rapid cycling as adults. Because the identification of rapid cycling requires a careful mapping of episodes during a minimum time span of 1 year, a description of its natural course requires a lengthy observation period. In addition, conclusions as to the possible effects of treatment on the course of rapid cycling require that the members of a cohort be followed up prospectively regardless of whether they remain in treatment. The National Institute of Mental Health Collaborative Depression Study meets these specifications, and the following analysis uses data from it to address 4 questions: (1) Are very early onsets more common among adults who display rapid cycling? (2) How persistent is rapid cycling? (3) Are bipolar patients who are prone to this phenomenon more likely to experience manic or hypomanic syndromes while taking antidepressants than are other bipolar patients? (4) Is the resolution of rapid cycling associated with lower rates of antidepressant use? Our earlier report on the natural course of rapidcycling bipolar disorder began with the same cohort but described a substantially shorter observation period. 6 Moreover, because no fully operational definition of rapid cycling had then been published, we used one that seemed to best approximate the definitions provided in existing publications. The DSM-IV now lists clear criteria, but these differ in several respects from those we used earlier. Maj et al 16 showed that seemingly subtle variations in how rapid cycling is defined can have important effects on its prognostic significance. Given the wide use of the DSM-IV definition, it is important that the demographics and natural course of rapid cycling be described with the use of that definition. METHODS SUBJECTS Between 1978 and 1981, the National Institute of Mental Health Collaborative Program on the Psychobiology of Depression Clinical Studies recruited patients as they sought treatment for affective illness at any of 5 academic centers: Massachusetts General Hospital and Harvard University in Boston; Rush Presbyterian St Luke s Medical Center in Chicago, Ill; University of Iowa College of Medicine in Iowa City; New York State Psychiatric Institute and Columbia University in New York; and Washington University School of Medicine in St Louis, Mo. All patients were white, English speaking, and knowledgeable of their biological parents, and all met Research Diagnostic Criteria (RDC) 17 for major depressive disorder, schizoaffective disorder, or manic disorder. Each participant provided informed consent. The subjects described in the following analyses were limited to those who, at intake, met RDC for bipolar affective disorder, type I or II, or for schizoaffective disorder, manic type, other than the mainly schizophrenic subtype. Also included were subjects who met criteria for nonbipolar major depressive disorder at intake but who subsequently developed an episode of mania, hypomania, or schizoaffective disorder manic type. We used DSM-IV criteria to identify as rapid cyclers those patients who manifested, during any 52-week period of the follow-up, 4 or more mood episodes, each lasting 2 or more weeks, during which RDC for major depressive disorder, mania, hypomania, schizoaffective mania, or schizoaffective depression were met. Episodes or phases were separated either by switches to an opposite pole or by remissions lasting 8 or more weeks. A remission required 8 contiguous weeks with no more than 2 symptoms present to no more than a mild degree. PROCEDURES Intake assessments included the Schedule for Affective Disorders and Schizophrenia. 18 Ratings on this scale reflected information from direct patient interview, from informants, and from a review of medical records. 915

3 Raters recontacted probands at 6-month intervals for the first 5 years of follow-up and annually thereafter. They used information from direct patient interview and from medical records to complete the Longitudinal Interval Follow-up Evaluation (LIFE) 19 during the first 2 years, the LIFE II in years 2 to 5, and the Streamlined Longitudinal Interval Continuation Evaluation in the sixth year and beyond. The LIFE II and Streamlined Longitudinal Interval Continuation Evaluation differed from the LIFE in the omission of some psychosocial comparisons. These instruments tracked each RDC syndrome on a weekby-week basis. The interviewers identified change points for each syndrome active since the last assessment and derived symptom levels for each interval. The Psychiatric Status Rating used 6 levels for major depressive disorder, manic disorder, and schizoaffective disorder. A score of 1 indicated no symptoms and a 2 indicated the presence of no more than 1 or 2 symptoms to a mild degree. A 5 indicated a full syndrome and a 6, a relatively severe, full syndrome. Other RDC syndromes were rated on 3-point scales, and, for these, a 3 indicated the presence of a full syndrome. Eight consecutive weeks with no ratings greater than 2 indicated recovery from a specified syndrome, and a recurrence required the redevelopment of a full syndrome. The LIFE instruments also quantified psychosocial functioning in discrete areas of employment, household maintenance, academic work, interfamilial relationships, relationships with friends, and recreation. The LIFE Range of Impaired Functioning Tool condenses these various domain ratings to a single score with demonstrable reliability and validity. 20 Participation did not determine or influence treatment. Raters, though, systematically quantified all somatic treatment directed at mental disorders and, for each week, listed all individual drugs and their doses. 21 The following analyses entered treatment dichotomously as present or absent for any given week and separately considered lithium carbonate, valproate sodium, carbamazepine, TCAs, monoamine oxidase inhibitors, and SSRIs. ANALYSIS Survival analyses were used to quantify the persistence of rapid cycling patterns. These describe the time from the end of the first year in which rapid cycling was observed to the beginning of the first year in which rapid cycling was absent. Loss to follow-up was a censoring variable. In the absence of any widely accepted definition of rapid cycling resolution, we used 2 provisional ones. A narrow one specified the first year that encompassed no more than 1 episode and in which no switching occurred. The second, broader one identified the first year that encompassed no more than 2 episodes and no more than 1 switch. To determine whether patients who were prone to rapid cycling were more likely to develop manic or hypomanic symptoms while taking antidepressants, we focused on lithium and the TCAs. As will be shown, lithium was by far the dominant mood stabilizer prescribed for this cohort, and TCAs were used more than any other class of antidepressants. Moreover, the TCAs have been more strongly implicated than have the SSRIs in the provocation both of manic switches 13 and of rapid cycling. 22 Exposure to other mood stabilizers during this observation period was too limited to support analyses concerning their effects. The analyses compared those with any rapid cycling during follow-up with the remaining bipolar patients by the proportion of weeks in which manic or hypomanic symptoms coincided with antidepressant use. Thus, the number of weeks during which both Psychiatric Status Ratings for mania, hypomania, or schizoaffective mania were greater than 2, and any TCA treatment was ongoing, composed the numerator. The number of weeks with ongoing TCA treatment, regardless of coincident symptoms, composed the denominator. A daily TCA dose greater than an imipramine hydrochloride equivalent of 100 mg constituted ongoing TCA treatment. The likelihood of depressive symptoms during TCA treatment was similarly quantified. Depression was considered present when the Psychiatric Status Rating for major depressive disorder, schizoaffective depression, intermittent depression, or minor depression exceeded 2. To detect any association between the resolution of rapid cycling and changes in the use of TCAs, analyses focused on the use of TCAs in the final 52 weeks of the first rapidcycling period observed during follow-up and on the subsequent 52 weeks representing the first year in which rapid cycling was no longer present. We chose not to simply compare the number of weeks of TCA use in the 2 periods because a resolution of rapid cycling implies less psychopathology generally and, because less morbidity leads to less treatment, an association between the resolution of rapid cycling and a decreased use of TCAs may have been artifactual. Instead, the analyses considered only weeks during which depressive symptoms were present and compared the 2 periods by the proportion of those weeks during which TCAs were prescribed. Those who developed rapid cycling during follow-up were compared with those who did not by means of 2 tests for categorical variables and t tests for continuous variables. A 2-tailed level of.05 was used for each statistical test. RESULTS Of 345 patients who met inclusion criteria for this analysis, 89 (25.8%) met DSM-IV criteria for rapid cycling during at least 1 of the years of prospective observation. Sixtynine (78%) of these patients displayed rapid cycling in the first year of follow-up, and another 11 (12%) began rapid cycling in the second year. Only 1 patient had the onset of rapid cycling later than the eighth year of followup. The modal number switches in the first year of rapid cycling was 4 (40 subjects); 33 (37%) had fewer than 4 switches, and only 1 (1%) had 10 or more. Forty-six (52%) had no periods of remission (2 or more symptom-free months) during that year. This group was followed up for a mean (SD) of 15.2 (4.9) years and the remaining bipolar patients were followed up for a shorter mean (SD) of 13.2 (6.4) years (t 343 = 2.54, P=.01). More than two thirds of those who developed a rapid-cycling pattern were female, while the sex ratio for the remaining patients was nearly even (Table 1). Bipolar II disorder was not more frequent among those prone to rapid-cycling patterns. These patients were somewhat more likely to be in a depressed or mixed state at the beginning of follow-up and had had, on average, more than twice as many previous episodes of affective disorder. Although the 2 groups were similar in ages at intake, those who developed rapid cycling were significantly younger when they first met criteria for an affective disorder. Distributions of age at onset showed that onsets in childhood and in early puberty accounted for this difference (Figure 1). With the threshold for earlyonset bipolar disorder proposed by Geller et al, (30%) of the rapid-cycling patients and 40 (15.6%) of the remaining bipolar patients had an onset at age 16 years or younger ( 2 1=9.75, P.005). 916

4 Table 1. Baseline Measures Any Rapid Cycling During Follow-up (n = 89) No Rapid Cycling During Follow-up (n = 256) Sex, No. (%) F* 62 (69.7) 137 (53.5) Inpatient, No. (%) 71 (79.8) 214 (83.6) Age at intake, mean (SD), y 36.0 (11.8) 36.1 (13.0) Age at first outpatient contact, 23.4 (8.6) 25.3 (10.0) mean (SD), y Age at first episode of affective 21.6 (8.9) 24.4 (10.6) disorder, mean (SD), y No. of previous episodes, 26.5 (49.6) 11.1 (29.0) mean (SD) Bipolar I, No. (%) 66 (74.2) 181 (70.7) Bipolar II, No. (%) 29 (32.6) 89 (34.8) Polarity at intake, No. (%) Depressed 57 (64.0) 140 (54.7) Manic 22 (24.7) 97 (37.9) Mixed 9 (10.1) 16 (6.2) * 2 1 = 7.0, P =.008. t 343 = 2.2, P =.03. t 343 = 3.54, P.006. Data were missing for 1 subject in the group with any rapid cycling during follow-up and for 3 subjects in the group with no rapid cycling during follow-up. Among rapid-cycling patients, the 27 with onsets before age 17 years did not differ from the remaining 62 by liability to switching or by the quantity of affective morbidity during follow-up. Rapid-cycling patients with early onsets and those with later onsets experienced means (SDs) of 2.5 (1.3) and 2.5 (1.5) switches per year, respectively. The respective mean (SD) proportions of follow-up weeks with depressive symptoms were 0.48 (0.26) and 0.39 (0.27) (t 87 =1.48, P=.14). The mean (SD) proportions of weeks with manic symptoms were 0.11 (0.11) and (0.14), respectively (t 87 = 0.93, P=.36). Over all weeks of follow-up, those who at any time showed a rapid-cycling course experienced depressive symptoms for 0.42 (SD, 0.27) of the follow-up weeks, a significantly higher proportion than the 0.30 (SD, 0.30) seen among the remaining bipolar patients (t 343 = 3.31, P=.001). Rapid-cycling patients also tended to experience more weeks with manic or hypomanic symptoms. Such symptoms were present during 0.13 (SD, 0.13) of the follow-up weeks among rapid cyclers and during 0.09 (0.16) of the weeks among nonrapid cyclers (t 343 = 1.91, P=.06). The mean ratio of weeks depressed to weeks manic or hypomanic was 11.1 (SD, 18.7) for rapid cyclers and 32.6 (SD, 97.9) for non rapid cyclers (t 343 =2.05, P=.04). The higher symptom levels that characterized patients prone to rapid cycling were reflected in greater overall functional impairment. The mean (SD) LIFE Range of Impaired Functioning Tool scores for these patients, and for the remaining bipolar patients, were 11.9 (2.4) and 10.7 (2.7), respectively (t 343 = 3.56, P.001). Only 20 patients manifested rapid cycling for 2 or more consecutive years. Of these, 13 displayed the pattern for only 2 years, 4 for only 3 years, 3 for 4 years. The 20 with 2 or more consecutive years of rapid cycling did not differ significantly from the remaining 69 by any of the variables listed in Table 1. % With Onset Age at Onset, y Figure 1. Age at onset in bipolar affective disorder. % With Persistence of Rapid Cycling Rapid Cycling (n = 89) No Rapid Cycling (n = 256) Weeks From End of First Year of Rapid Cycling Narrow Broad Figure 2. The resolution of rapid cycling by definition, n=83. The narrow definition specified a first year that encompassed no more than 1 episode and in which no switching occurred. The broad definition identified a first year that encompassed no more than 2 episodes and no more than 1 switch. More than 4 in 5 episodes of rapid cycling were observed to end whether the threshold for this required fewer than 3 episodes or 2 switches in a 1-year period, or fewer than 2 episodes and no switches (Figure 2). Six subjects had no follow-up beyond their first year of rapid cycling and were therefore omitted from this analysis. According to Kaplan-Meier estimates from the survival analyses, the median number of weeks from the end of the first year in which rapid cycling was observed, to the beginning of the first year of stabilization, was 6 for the first definition and 23 for the second, stricter definition. Of patients whose rapid-cycling pattern was observed to resolve according to the broader definition, 64 had at least some weeks of depression during the year of stabilization. These patients were no less likely to have taken TCAs while depressed in the period after the resolution of rapid cycling than they had in the preceding year when rapid cycling was ongoing. Tricyclic antidepressants were prescribed for 32.1% (SD, 42.6%) of the 2035 person-weeks with depression observed during the first year of resolution; the corresponding percentage for the preceding year was 28.8% (SD, 34.8%) during 2003 person-weeks with depression. Nor did these 2 years differ 917

5 Table 2. Treatment Conditions and Morbidity During Follow-up Treatment % of Weeks of Each Treatment, Mean (SD) Any Rapid Cycling (n = 89) No Rapid Cycling (n = 256) Lithium carbonate 45.0 (37.1) 45.2 (40.0) TCAs 24.0 (24.0) 20.0 (23.0) MAOIs 4.3 (15.4) 3.9 (12.6) SSRIs* 7.2 (11.9) 4.1 (10.0) Lithium with TCA 13.7 (20.9) 7.7 (16.8) Lithium without TCA 31.2 (31.5) 37.4 (38.1) TCA without lithium 5.5 (9.0) 5.7 (12.2) Carbamazepine 5.1 (13.3) 3.4 (10.9) Valproate sodium 2.6 (5.5) 1.1 (4.3) Abbreviations: MAOIs, monoamine oxidase inhibitors; SSRIs, selective serotonin reuptake inhibitors; TCAs, tricyclic antidepressants. *t 343 = 2.43, P =.02. t 343 = 2.72, P =.007. t 343 = 2.59, P =.01. Table 3. Manic or Hypomanic and Depressive Symptoms During Lithium Carbonate Therapy With or Without TCAs Any Rapid Cycling No Rapid Cycling Person-weeks of treatment with lithium + TCA % Of weeks with mania or hypomania, 17.3 (27.1) 9.5 (22.6) mean (SD) % Of weeks with depression, mean (SD) 56.2 (35.8) 61.8 (37.5) Person-weeks of treatment with lithium without TCA % Of weeks with mania or hypomania, 21.5 (26.0) 15.9 (25.6) mean (SD) % Of weeks with depression, mean (SD)* 46.8 (36.2) 28.6 (36.4) Abbreviation: TCAs, tricyclic antidepressants. *t 286 = 3.80, P.001. in the percentage of weeks during which mood stabilizers (lithium, carbamazepine, or valproate sodium) were prescribed. These were 48.7% (SD, 45.8%) for the rapidcycling year and 49.3% (SD, 47.3%) for the following year. Bipolar patients who displayed any rapid cycling took SSRIs, lithium with TCAs, and valproate for greater proportions of the follow-up weeks than did those who showed no rapid cycling (Table 2). Otherwise, the groups had similar treatment exposures. During periods when lithium was being taken without TCAs, patients prone to rapid cycling were significantly more likely to be experiencing depressive symptoms than were other bipolar patients (Table 3). During weeks when lithium was taken with a TCA, patients in the 2 groups had similar likelihoods of depressive symptoms. Patients prone to rapid cycling were somewhat more likely than other bipolar patients to have manic or hypomanic symptoms in any given week during lithium treatment, but this was true both in the presence and in the absence of TCAs. We considered whether patients prone to rapid cycling were more likely to have been taking a TCA during those weeks immediately preceding a switch from depression to mania or hypomania than they were during Table 4. Switches From Depression to Mania or Hypomania and TCA Use Among 89 Patients Prone to Rapid Cycling Weeks Preceding at Switch All Other Weeks With Depression Total person-weeks observed No. (%) of weeks with any TCA 136 (28.8) 7140 (29.8) No. (%) of weeks with any lithium 95 (20.1) 4164 (17.4) carbonate + TCA No. (%) of weeks with any lithium 143 (30.3) 6983 (29.1) without TCA No. (%) of weeks with any TCA without lithium* 41 (8.7) 2976 (12.4) Abbreviation: TCA, tricyclic antidepressant. * 2 1 = 6.6, P =.01. Table 5. Suicidal Behaviors Before Intake and During Follow-up Any Rapid Cycling (n = 89) No Rapid Cycling (n = 256) Before intake, No. (%) Any attempt* 51 (57.3) 85 (33.2) Any attempt of high intent 31 (34.8) 38 (14.8) Any attempt of high lethality 36 (40.4) 35 (13.7) After intake, No. (%) Completed suicide 3 (3.4) 11 (4.3) Any attempt 46 (51.7) 70 (27.3) Any attempt of high intent 27 (30.3) 33 (12.9) Any attempt of high lethality 30 (33.7) 36 (14.1) * 2 1 = 16.1, P = 16.5, P = 29.0, P = 17.5, P = 14.0, P = 16.5, P.001. other weeks. The results did not implicate TCAs in these switches (Table 4). These patients were no more likely to have been taking a TCA, with or without lithium, during the weeks preceding a switch from depression to mania than they were during any other week when depression was present. Although patients with rapid cycling were not more likely to commit suicide (Table 5), they were more likely than the remaining bipolar patients to have made attempts before study intake and to make them during the follow-up period. Group differences were particularly large for attempts rated as being high in intent or in potential medical lethality. Sex is a well-known risk factor for attempted suicide, and females were overrepresented in the rapidcycling group. A logistic regression analysis with sex and the presence or absence of rapid cycling as independent variables showed that both were significantly associated with the likelihood of suicide attempts during followup. The odds ratios were 2.0 (95% confidence interval, ) for female sex (Wald 2 =7.5, P=.006) and 2.6 (95% confidence interval, ) for rapid cycling (Wald 2 =13.8, P.001). 918

6 National Institute of Mental Health Collaborative Program on the Psychobiology of Depression Clinical Studies The National Institute of Mental Health Collaborative Program on the Psychobiology of Depression Clinical Studies was conducted with the participation of the following investigators: M. B. Keller, MD (Chairperson, Providence, RI); W. Coryell, MD (Co-chairperson, Iowa City, Iowa); T. I. Mueller, MD, D. Solomon, MD (Providence); J. Fawcett, MD, W. A. Scheftner, MD (Chicago, Ill); W. Coryell, MD, J. Haley (Iowa City); J. Endicott, PhD, A. C. Leon, PhD, J. Loth, MSW (New York, NY); J. Rice, PhD, T. Reich, MD (St Louis, Mo). Other contributors include H. S. Akiskal, MD, N. C. Andreasen, MD, PhD, P. J. Clayton, MD, J. Croughan, MD, R. M. A. Hirschfeld, MD, L. Judd, MD, M. M. Katz, PhD, P. W. Lavori, PhD, J. D. Maser, PhD, M. T. Shea, PhD, R. L. Spitzer, MD, M. A. Young, PhD. Deceased: G. L. Klerman, MD, E. Robins, MD, R. W. Shapiro, MD, G. Winokur, MD. COMMENT Bipolar patients who developed a rapid-cycling pattern at any time during follow-up were more likely than those who did not to have had onsets before 17 years of age, were more likely to make serious suicide attempts during follow-up, and were much more likely to have depressive symptoms during any given week. The greater depressive morbidity experienced by patients prone to rapid cycling was reflected in their increased exposure to TCAs while taking lithium. They were somewhat more likely to experience mania or hypomania while taking lithium, but this was true whether or not TCAs were also present. Moreover, TCAs were no more often present in weeks preceding shifts from depression to mania or hypomania than in other weeks when depression was present. Although the course of patients who showed rapid cycling patterns differed in several ways from the course of bipolar patients without it, rapid cycling in itself was a transient phenomenon in the majority of cases. It is likely, though, that the persistence of rapid cycling when identified prospectively, as in this study, will be less than that seen in samples selected for a current rapid-cycling pattern, as the latter method will oversample patients whose rapid cycling is truly chronic. It is notable, then, that the only other report to quantify the persistence of rapid cycling during a lengthy follow-up found that a similar 19% continued to show this pattern. 4 On the other hand, the current sample was recruited at tertiary care centers and the patients described by Maj et al 4 all attended a clinic specializing in affective disorders. As such, patients with refractory disease were probably overrepresented in both samples relative to patients typically seen by private practitioners. These analyses found no association between the cessation of rapid-cycling patterns and any decrease in the use of TCAs to treat depressive symptoms during lithium maintenance. Notably, another recent report found that the discontinuation of antidepressants in a group of bipolar patients was associated, not with a decrease in cycling, but with an increase in depressive morbidity. 24 Bipolar patients who manifested rapid cycling resembled those who did not by the proportion of follow-up weeks during which they were treated with lithium and/or TCAs. The proportion of weeks with SSRI treatment was low in both groups but significantly higher for those with rapid cycling. This may have reflected the fact that the somewhat longer observation period for this group extended further into the period when SSRIs were displacing TCAs. The numbers of weeks observed during SSRI treatment were quite small for both groups, though, and this precluded efforts to determine their effects on affective stability. While taking lithium, patients prone to rapid cycling were not significantly more likely to manifest manic or hypomanic symptoms when TCAs were also present than were patients who showed no such liability. Nor was the use of TCAs associated with an increased risk for switching in this affectively unstable group. Because TCAs have been more strongly implicated than other antidepressants in the promotion of such switches, these results probably apply as well to the newer antidepressants. This has important implications for the management of bipolar depression generally and for rapid cycling in particular. Switches did indeed occur while TCAs were being used, but they occurred no less frequently when TCAs were not in use. These findings are quite consistent with those of studies with placebo control. Three groups have randomly assigned bipolar patients to treatment with lithium with placebo or lithium with TCAs for prophylaxis, and none found manic episodes to be significantly more likely among the latter patients Similarly, a naturalistic study of outpatients with bipolar I maintained on a regimen of mood stabilizers (predominantly lithium) found that depressive episodes in which TCAs were used were no more likely to end in switches than were depressive episodes managed without antidepressants. 28 Rapid-cycling patients were more than twice as likely as other bipolar patients to have a history of severe suicide attempts at the beginning of follow-up, and to make further serious attempts during follow-up. This is consistent with our finding that rapid-cycling patients were depressed for significantly greater proportions of the follow-up and, presumably, experienced more depression before they entered follow-up. The abrupt transitions from mania or hypomania to depression that many of these patients experience may further predispose to suicidality. It is notable, though, that no trend emerged to indicate that rapid cyclers were at greater risk for completed suicide despite the large group differences in serious attempt rates. A clear association between suicidality and rapid cycling has not emerged in earlier descriptions, although Bauer et al 29 and Maj et al 4 described strong trends in this direction. Wu and Dunner 30 specifically sought an association between rapid cycling and suicide attempts in a 919

7 chart review of bipolar patients and found none. Their sample was drawn from a well-known specialty clinic and contained a large proportion of patients with treatmentrefractory disease, however. Whether such an association is characteristic of more representative samples awaits further study. Early onsets were overrepresented among adult patients prone to rapid cycling, and yet rapid-cycling patients with an onset of bipolar illness before the age of 17 years resembled other rapid-cycling patients in their propensity to switching and in overall manic or depressive morbidity over time. Although these data cannot determine the direct effects of prepubertal and early pubertal periods on the propensity to rapid cycling, they do indicate that the very early onset of bipolar disorder may convey a lifelong propensity to this phenomenon. Submitted for publication May 7, 2002; final revision received January 24, 2003; accepted January 27, This study was supported by grants MH25416 and MH51324 from the National Institute of Mental Health, Bethesda, Md. This article has been reviewed by the Publication Committee of the Collaborative Depression Study and has its endorsement. Corresponding author: William Coryell, MD, Psychiatry Research MEB, Room 2-205, University of Iowa Health Care, Iowa City, IA ( REFERENCES 1. Dunner DL, Fieve RR. Clinical factors in lithium carbonate prophylaxis failure. Arch Gen Psychiatry. 1974;30: Post RM, Robinson DR, Ballenger JC. Conditioning and sensitization in the longitudinal course of affective illness. Br J Psychiatry. 1986;149: Post RM. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry. 1992;149: Maj M, Magliano L, Pirozzi R, Marasco C, Guarneri M. Validity of rapid cycling as a course specifier for bipolar disorder. Am J Psychiatry. 1994;151: Goldberg JF, Harrow M. Kindling in bipolar disorders: a longitudinal follow-up study. Biol Psychiatry. 1994;35: Coryell W, Endicott J, Keller M. Rapidly cycling affective disorder: demographics, diagnosis, family history, and course. Arch Gen Psychiatry. 1992;49: Kukopulos A, Reginaldi D, Laddomada P, Floris G, Serra G, Tondo L. Course of the manic depressive cycle and changes caused by treatment. Pharmakopsychiatr Neuropsychopharmakol. 1980;13: Wehr TA, Sack D, Rosenthal N, Cowdry R. Rapid cycling affective disorder: contributing factors and treatment responses in fifty-one patients. Am J Psychiatry. 1988;145: Turvey CL, Coryell WH, Arndt S, Solomon DA, Leon AC, Endicott J, Mueller T, Keller M, Akiskal H. Polarity sequence, depression, and chronicity in bipolar I disorder. J Nerv Ment Dis. 1999;187: Baldessarini RJ, Tondo L, Floris G, Hennen J. Effects of rapid cycling on response to lithium maintenance treatment in 360 bipolar I and II disorder patients. J Affect Disord. 2000;61: Coryell W. Can antidepressants induce rapid cycling? Arch Gen Psychiatry. 1993; 50: Keller MB, Lavori PW, Coryell W, et al. Differential outcome of pure manic, mixed/ cycling, and pure depressive episodes in patients with bipolar illness. JAMA. 1986; 255: Peet M. Induction of mania with selective serotonin reuptake inhibitors and tricyclic antidepressants. Br J Psychiatry. 1994;164: Geller B, Sun K, Zimmerman B, Luby J, Frazier J, Williams M. Complex and rapid cycling in bipolar children and adolescents: a preliminary study. J Affect Disord. 1995;34: Geller B, Craney JL, Bolhofner K, delbello MP, Williams M, Zimmerman B. Oneyear recovery and relapse rates of children with a prepubertal and early adolescent bipolar disorder phenotype. Am J Psychiatry. 2001;158: Maj M, Trozzi R, Formacola AMR, Tortorella A. Reliability and validity of four alternative definitions of rapid cycling bipolar disorder. Am J Psychiatry. 1999; 156: Spitzer RL, Endicott J, Robins E. Research Diagnostic Criteria: rationale and reliability. Arch Gen Psychiatry. 1978;35: Endicott J, Spitzer AL. Kindling in bipolar disorders: a longitudinal follow-up study. Arch Gen Psychiatry. 1978;35: Keller MB, Lavori PW, Friedman B, Nielsen E, Endicott J, McDonald-Scott P, Andreasen NC. The Longitudinal Interval Follow-up Evaluation. Arch Gen Psychiatry. 1987;44: Leon AC, Solomon DA, Mueller TI, Turvey CL, Endicott J, Keller MB. The range of impaired functioning tool (LIFE-RIFT): a brief measure of functional impairment. Psychol Med. 1999;29: Keller MB, Lavori PW, Klerman GL, Andreasen NC, Endicott J, Coryell W, Fawcett J, Rice JP, Hirschfeld RM. Low levels and lack of predictors of somatotherapy and psychotherapy received by depressed patients. Arch Gen Psychiatry. 1986;43: Wehr TA, Goodwin FK. Rapid cycling in manic depressives induced by tricyclic antidepressants. Arch Gen Psychiatry. 1979;36: Geller B, Zimerman B, Williams M, Bolhofner K, Craney JL, Delbello MP, Soutullo CA. Six-month stability and outcome of a prepubertal and early adolescent bipolar disorder phenotype. J Child Adolesc Psychopharmacol. 2000;10: Altshuler LL, Kiriakos L, Calcagno J, Goodman R, Gitlin M, Frye M, Mintz J. The impact of antidepressant discontinuation versus antidepressant continuation on 1-year risk for relapse of bipolar depression: a retrospective chart review. J Clin Psychiatry. 2001;62: Quitkin FM, Kane J, Rifkin A, Ramos-Lorenzi JR, Nayak DV. Prophylactic lithium carbonate with and without imipramine for bipolar I patients: a double-blind study. Arch Gen Psychiatry. 1981;38: Prien RF, Kupfer DJ, Mansky PA, Small JG, Tuason VB, Voss CB, Johnson WE. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders: report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate imipramine combination. Arch Gen Psychiatry. 1984;41: Nemeroff CB, Evans DL, Gyulai L, Sachs GS, Bowden CL, Gergel IP, Oakes R, Pitts CD. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry. 2001;158: Boerlin HL, Gitlin MJ, Zoellner LA, Hammen CL. Bipolar depression and antidepressant-induced mania: a naturalistic study. J Clin Psychiatry. 1998;59: Bauer MS, Calabrese J, Dunner DL, Post R, Whybrow PC, Gyulai L, Tay LK, Youkin SR, Bynum D, Lavori P, Price RA. Multisite data reanalysis of the validity of rapid cycling as a course modified for bipolar disorder in DSM-IV. Am J Psychiatry. 1994;151: Wu LH, Dunner DL. Suicide attempts in rapid cycling bipolar disorder patients. J Affect Disord. 1993;29:

Family History and Symptom Levels during Treatment for Bipolar I Affective Disorder

Family History and Symptom Levels during Treatment for Bipolar I Affective Disorder Family History and Symptom Levels during Treatment for Bipolar I Affective Disorder William Coryell, Hagop Akiskal, Andrew C. Leon, Carolyn Turvey, David Solomon, and Jean Endicott Background: Studies

More information

ORIGINAL ARTICLE. Psychosocial Disability in the Course of Bipolar I and II Disorders

ORIGINAL ARTICLE. Psychosocial Disability in the Course of Bipolar I and II Disorders ORIGINAL ARTICLE Psychosocial Disability in the Course of Bipolar I and II Disorders A Prospective, Comparative, Longitudinal Study Lewis L. Judd, MD; Hagop S. Akiskal, MD; Pamela J. Schettler, PhD; Jean

More information

Commentary: Evidence-based pharmacotherapy of bipolar disorder

Commentary: Evidence-based pharmacotherapy of bipolar disorder International Journal of Neuropsychopharmacology (2003), 6, 303 308. Copyright f 2003 CINP DOI: 10.1017/S1461145703003626 Commentary: Evidence-based pharmacotherapy of bipolar disorder SPECIAL SERIES S.

More information

Multistate Outcome Analysis of Treatment MOAT

Multistate Outcome Analysis of Treatment MOAT Multistate Outcome Analysis of Treatment MOAT Charles L. Bowden, M.D. Presented with Fond Memories of an Outstanding Statistician and Investigative Scientist Andy Leon Design contributors to low generalizability

More information

Validity of Rapid Cycling as a Course Specifier for Bipolar Disorder

Validity of Rapid Cycling as a Course Specifier for Bipolar Disorder Validity of Rapid Cycling as a Course Specifier for Bipolar Disorder Mario Maj, M.D., Ph.D., Lorenza Magliano, M.D., Raffaele Pirozzi, M.D., Cecilia Marasco, M.D., and Manuela Guarneri, M.D. Objective:

More information

Recent research on bipolar disorder (BPD) has highlighted

Recent research on bipolar disorder (BPD) has highlighted Mood State at Study Entry as Predictor of the Polarity of Relapse in Bipolar Disorder Joseph R. Calabrese, Eduard Vieta, Rif El-Mallakh, Robert L. Findling, Eric A. Youngstrom, Omar Elhaj, Prashant Gajwani,

More information

Chapter 6 Mood Disorders and Suicide An Overview of Mood Disorders

Chapter 6 Mood Disorders and Suicide An Overview of Mood Disorders Page 1 Extremes in Normal Mood Chapter 6 Mood Disorders and Suicide An Overview of Mood Disorders Nature of depression Nature of mania and hypomania Types of DSM-IV Depressive Disorders Major depressive

More information

CHAIR SUMMIT 7TH ANNUAL #CHAIR2014. Master Class for Neuroscience Professional Development. September 11 13, Westin Tampa Harbour Island

CHAIR SUMMIT 7TH ANNUAL #CHAIR2014. Master Class for Neuroscience Professional Development. September 11 13, Westin Tampa Harbour Island #CHAIR2014 7TH ANNUAL CHAIR SUMMIT Master Class for Neuroscience Professional Development September 11 13, 2014 Westin Tampa Harbour Island Sponsored by #CHAIR2014 Bipolar Depression: Putting the End Goal

More information

Bipolar Disorders Expert Column Series Rapid-Cycling Bipolar Disorder: Emerging Treatments and Enduring Controversies

Bipolar Disorders Expert Column Series Rapid-Cycling Bipolar Disorder: Emerging Treatments and Enduring Controversies To Print: Click your browser's PRINT button. Bipolar Disorders Expert Column Series Rapid-Cycling Bipolar Disorder: Emerging Treatments and Enduring Controversies Joseph F. Goldberg, MD; Jinger Hoop, MD

More information

Preferred Practice Guidelines Bipolar Disorder in Children and Adolescents

Preferred Practice Guidelines Bipolar Disorder in Children and Adolescents BadgerCare Plus Preferred Practice Guidelines Bipolar Disorder in Children and Adolescents These Guidelines are based in part on the following: American Academy of Child and Adolescent Psychiatry s Practice

More information

Correlates of 1-Year Prospective Outcome in Bipolar Disorder: Results From the Stanley Foundation Bipolar Network

Correlates of 1-Year Prospective Outcome in Bipolar Disorder: Results From the Stanley Foundation Bipolar Network Article Correlates of 1-Year Prospective Outcome in Bipolar Disorder: Results From the Stanley Foundation Bipolar Network Willem A. Nolen, M.D., Ph.D. David A. Luckenbaugh, M.A. Lori L. Altshuler, M.D.

More information

Treatment Options for Bipolar Disorder Contents

Treatment Options for Bipolar Disorder Contents Keeping Your Balance Treatment Options for Bipolar Disorder Contents Medication Treatment for Bipolar Disorder 2 Page Medication Record 5 Psychosocial Treatments for Bipolar Disorder 6 Module Summary 8

More information

The Pharmacological Management of Bipolar Disorder: An Update

The Pharmacological Management of Bipolar Disorder: An Update Psychobiology Research Group The Pharmacological Management of Bipolar Disorder: An Update R. Hamish McAllister-Williams, MD, PhD, FRCPsych Reader in Clinical Psychopharmacology Newcastle University Hon.

More information

Optimal Length of Continuation Therapy in Depression: A Prospective Assessment During Long-Term Fluoxetine Treatment

Optimal Length of Continuation Therapy in Depression: A Prospective Assessment During Long-Term Fluoxetine Treatment Optimal Length of Continuation Therapy in Depression: A Prospective Assessment During Long-Term Fluoxetine Treatment Frederick W. Reimherr, M.D., Jay D. Amsterdam, M.D., Frederic M. Quitkin, M.D., Jerrold

More information

Dunner and Fieve (1) originally coined the term

Dunner and Fieve (1) originally coined the term Article The Prospective Course of Rapid-Cycling Bipolar Disorder: Findings From the STEP-BD Christopher D. Schneck, M.D. David J. Miklowitz, Ph.D. Sachiko Miyahara, M.S. Mako Araga, M.S. Stephen Wisniewski,

More information

Differentiating Unipolar vs Bipolar Depression in Children

Differentiating Unipolar vs Bipolar Depression in Children Differentiating Unipolar vs Bipolar Depression in Children Mai Uchida, M.D. Director, Center for Early Identification and Prevention of Pediatric Depression Massachusetts General Hospital Assistant Professor

More information

APPENDIX 11: CASE IDENTIFICATION STUDY CHARACTERISTICS AND RISK OF BIAS TABLES

APPENDIX 11: CASE IDENTIFICATION STUDY CHARACTERISTICS AND RISK OF BIAS TABLES APPENDIX 11: CASE IDENTIFICATION STUDY CHARACTERISTICS AND RISK OF BIAS TABLES 1 Study characteristics table... 3 2 Methodology checklist: the QUADAS-2 tool for studies of diagnostic test accuracy... 4

More information

Mset, with some episodes clearly linked to environmental

Mset, with some episodes clearly linked to environmental Prevention of Relapse and Recurrence in Depression: The Role of Long-Term Pharmacotherapy and Psychotherapy Andrew A. Nierenberg, M.D.; Timothy J. Petersen, Ph.D.; and Jonathan E. Alpert, M.D. Major depressive

More information

Bipolar disorder and alcoholism

Bipolar disorder and alcoholism Bipolar Disorder and Alcoholism Susan C. Sonne, PharmD, and Kathleen T. Brady, M.D., Ph.D. Bipolar disorder and alcoholism commonly co-occur. Multiple explanations for the relationship between these conditions

More information

Differentiating MDD vs. Bipolar Depression In Youth

Differentiating MDD vs. Bipolar Depression In Youth Differentiating MDD vs. Bipolar Depression In Youth Mai Uchida, M.D. Staff Physician Clinical and Research Programs in Pediatric Psychopharmacology Massachusetts General Hospital Disclosures Neither I

More information

Prospective assessment of treatment use by patients with personality disorders

Prospective assessment of treatment use by patients with personality disorders Wesleyan University From the SelectedWorks of Charles A. Sanislow, Ph.D. February, 2006 Prospective assessment of treatment use by Donna S. Bender Andrew E. Skodol Maria E. Pagano Ingrid R. Dyck Carlos

More information

With the preparation for the fifth edition of the Diagnostic

With the preparation for the fifth edition of the Diagnostic Article Diagnostic Crossover in Anorexia Nervosa and Bulimia Nervosa: Implications for DSM-V Kamryn T. Eddy, Ph.D. David J. Dorer, Ph.D. Debra L. Franko, Ph.D. Kavita Tahilani, B.S. Heather Thompson-Brenner,

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 05 May 2010

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 05 May 2010 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 05 May 2010 LAMICTAL 2 mg, dispersible / chewable tablet B/30 (CIP: 354 581-7) LAMICTAL 5 mg, dispersible / chewable

More information

Challenges in identifying and treating bipolar depression: a guide

Challenges in identifying and treating bipolar depression: a guide Challenges in identifying and treating bipolar depression: a guide Dr. Paul Stokes Clinical Senior Lecturer, Centre for Affective Disorders, Department of Psychological Medicine Overview Challenges in

More information

Clozapine as Add-On Medication in the Maintenance Treatment of Bipolar and Schizoaffective Disorders

Clozapine as Add-On Medication in the Maintenance Treatment of Bipolar and Schizoaffective Disorders Neuropsychobiology 2002;45(suppl 1):37 42 Clozapine as Add-On Medication in the Maintenance Treatment of Bipolar and Schizoaffective Disorders A Case Series B. Hummel S. Dittmann A. Forsthoff N. Matzner

More information

Relationship of Variability in Residual Symptoms With Recurrence of Major Depressive Disorder During Maintenance Treatment

Relationship of Variability in Residual Symptoms With Recurrence of Major Depressive Disorder During Maintenance Treatment Article Relationship of Variability in Residual Symptoms With Recurrence of Major Depressive Disorder During Maintenance Treatment Jordan F. Karp, M.D. Daniel J. Buysse, M.D. Patricia R. Houck, M.S.H.

More information

Article. Two-Year Prospective Follow-Up of Children. with a prepubertal and early adolescent. Bipolar Disorder Phenotype

Article. Two-Year Prospective Follow-Up of Children. with a prepubertal and early adolescent. Bipolar Disorder Phenotype Article Two-Year Prospective Follow-Up of Children With a Prepubertal and Early Adolescent Bipolar Disorder Phenotype Barbara Geller, M.D. James L. Craney, M.S., M.P.H. Kristine Bolhofner, B.S. Michael

More information

Your footnote

Your footnote MANIA Your footnote Your footnote Cipriani A, Barbui C, Salanti G et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. The Lancet 2011;

More information

RDC Alcoholism in Patients With Major. Affective Syndromes: Two-Year Course. Deborah S. Hasin, Ph.D., Jean Endicott, Ph.D., and Martin B. Keller, M.D.

RDC Alcoholism in Patients With Major. Affective Syndromes: Two-Year Course. Deborah S. Hasin, Ph.D., Jean Endicott, Ph.D., and Martin B. Keller, M.D. Regular Articles RDC Alcoholism in Patients With Major Affective Syndromes: Two-Year Course Deborah S. Hasin, Ph.D., Jean Endicott, Ph.D., and Martin B. Keller, M.D. The authors examined the 2-year course

More information

In the last few years, evidence for the efficacy of psychotherapy

In the last few years, evidence for the efficacy of psychotherapy Article Relapse Prevention in With Bipolar Disorder: Outcome After 2 Years Dominic H. Lam, Ph.D. Peter Hayward, Ph.D. Edward R. Watkins, Ph.D. Kim Wright, B.A. Pak Sham, Ph.D. Objective: In a previous

More information

Bipolar Disorder Clinical Practice Guideline Summary for Primary Care

Bipolar Disorder Clinical Practice Guideline Summary for Primary Care Bipolar Disorder Clinical Practice Guideline Summary for Primary Care DIAGNOSIS AND CLINICAL ASSESSMENT Bipolar Disorder is categorized by extreme mood cycling; manifested by periods of euphoria, grandiosity,

More information

Propensity score stratification for observational comparison of repeated binary outcomes

Propensity score stratification for observational comparison of repeated binary outcomes Statistics and Its Interface Volume 4 (2011) 489 498 Propensity score stratification for observational comparison of repeated binary outcomes Andrew C. Leon and Donald Hedeker A two-stage longitudinal

More information

What s new in the treatment of bipolar disorder?

What s new in the treatment of bipolar disorder? What s new in the treatment of bipolar disorder? Dr. David Cousins MRC Clinician Scientist Institute of Neuroscience Newcastle University NCMD 2017 What s new in the treatment of bipolar disorder? Dr.

More information

This chapter discusses disorders characterized by abnormalities of mood: namely, Mood Disorders

This chapter discusses disorders characterized by abnormalities of mood: namely, Mood Disorders CHAPTER 1 Mood Disorders Description of mood disorders The bipolar spectrum Can unipolar depression be distinguished from bipolar depression? Are mood disorders progressive? Neurotransmitters and circuits

More information

Suitable dose and duration of fluvoxamine administration to treat depression

Suitable dose and duration of fluvoxamine administration to treat depression PCN Psychiatric and Clinical Neurosciences 1323-13162003 Blackwell Science Pty Ltd 572April 2003 1098 Dose and duration of fluvoxamine S. Morishita and S. Arita 10.1046/j.1323-1316.2002.01098.x Original

More information

Introducing a Clinical Course-Graphing Scale for DSM-5 Mood Disorders

Introducing a Clinical Course-Graphing Scale for DSM-5 Mood Disorders Introducing a Clinical Course-Graphing Scale for DSM-5 Mood Disorders JAMES P. MCCULLOUGH, Jr., Ph.D.* SARAH W. CLARK, M.S.* DANIEL N. KLEIN, Ph.D.# MICHAEL B. FIRST, M.D. Assessment of clinical course

More information

September 26 28, 2013 Westin Tampa Harbour Island. Co-sponsored by

September 26 28, 2013 Westin Tampa Harbour Island. Co-sponsored by September 26 28, 2013 Westin Tampa Harbour Island Co-sponsored by Best Practices in the Management of Bipolar Disorder Robert M. A. Hirschfeld, MD University of Texas Medical Branch Galveston, TX Peter

More information

The impact of the number of episodes on the outcome of Bipolar Disorder

The impact of the number of episodes on the outcome of Bipolar Disorder Eur. J. Psychiat. Vol. 20, N. 1, (21-28) 2006 Key words: Recurrence, Bipolar disorder, Outcome. The impact of the number of episodes on the outcome of Bipolar Disorder S. Di Marzo, M.D.*, ** A. Giordano,*,

More information

Patients in the MIDAS Project. Exclusion Due to Bipolarity or Psychosis. Results

Patients in the MIDAS Project. Exclusion Due to Bipolarity or Psychosis. Results Things You Think You Know Things You Think You Know, That May Not Be True in the Diagnosis and Treatment of Depression Mark Zimmerman, MD Director of Outpatient Psychiatry Director of the Partial Hospital

More information

Comprehensive Quick Reference Handout on Pediatric Bipolar Disorder By Jessica Tomasula

Comprehensive Quick Reference Handout on Pediatric Bipolar Disorder By Jessica Tomasula Comprehensive Quick Reference Handout on Pediatric Bipolar Disorder By Jessica Tomasula Official Name Bipolar Disorder; also referred to as Manic Depression Definitions (DSM-IV-TR, 2000) Bipolar I Disorder

More information

1 1 Evidence-based pharmacotherapy of major depressive disorder. Michael J. Ostacher, Jeffrey Huffman, Roy Perlis, and Andrew A.

1 1 Evidence-based pharmacotherapy of major depressive disorder. Michael J. Ostacher, Jeffrey Huffman, Roy Perlis, and Andrew A. 1 1 Evidence-based pharmacotherapy of major depressive disorder Michael J. Ostacher, Jeffrey Huffman, Roy Perlis, and Andrew A. Nierenberg Massachusetts General Hospital and Harvard University, Boston,

More information

Bipolar Disorder in Youth

Bipolar Disorder in Youth Bipolar Disorder in Youth Janet Wozniak, M.D. Associate Professor of Psychiatry Director, Pediatric Bipolar Disorder Research Program Harvard Medical School Massachusetts General Hospital Pediatric-Onset

More information

It's Cycling, Not Polarity Understanding and Diagnosing the Bipolar Spectrum

It's Cycling, Not Polarity Understanding and Diagnosing the Bipolar Spectrum It's Cycling, Not Polarity Understanding and Diagnosing the Bipolar Spectrum Session 4022: American Psychiatric Nurses Association National Conference, Louisville, KY Andrew Penn, RN, MS, NP, CNS Psychiatric

More information

Clinical experience suggests. Ten-Year Use of Mental Health Services by Patients With Borderline Personality Disorder and With Other Axis II Disorders

Clinical experience suggests. Ten-Year Use of Mental Health Services by Patients With Borderline Personality Disorder and With Other Axis II Disorders Ten-Year Use of Mental Health Services by Patients With Borderline Personality Disorder and With Other Axis II Disorders Susanne Hörz, Dipl.-Psych., Ph.D. Mary C. Zanarini, Ed.D. Frances R. Frankenburg,

More information

Panic disorder and anxiety symptoms are hypothesized

Panic disorder and anxiety symptoms are hypothesized Article Anxiety in Major Depression: Relationship to Suicide Attempts Giovanni P.A. Placidi, M.D. Maria A. Oquendo, M.D. Kevin M. Malone, M.D. Beth Brodsky, Ph.D. Steven P. Ellis, Ph.D. J. John Mann, M.D.

More information

Cover Page. The handle holds various files of this Leiden University dissertation.

Cover Page. The handle   holds various files of this Leiden University dissertation. Cover Page The handle http://hdl.handle.net/1887/38787 holds various files of this Leiden University dissertation. Author: Koenders, Manja Title: Tangled up in mood : predicting the disease course of bipolar

More information

Developing bipolar disorder. A study among children of patients with bipolar disorder Hillegers, Manon Hubertine Johanna

Developing bipolar disorder. A study among children of patients with bipolar disorder Hillegers, Manon Hubertine Johanna University of Groningen Developing bipolar disorder. A study among children of patients with bipolar disorder Hillegers, Manon Hubertine Johanna IMPORTANT NOTE: You are advised to consult the publisher's

More information

CONTROVERSIES AND NEW DIRECTIONS

CONTROVERSIES AND NEW DIRECTIONS BIPOLAR Introduction DISORDER IN CHILDHOOD AND EARLY ADOLESCENCE Introduction MELISSA P. D ELBELLO, DAVID AXELSON, and BARBARA GELLER CONTROVERSIES AND NEW DIRECTIONS Although the existence and diagnostic

More information

As we have seen, bipolar disorder is a

As we have seen, bipolar disorder is a LONG-TERM MOOD STABILIZATION: PHARMACOLOGIC TREATMENT STRATEGIES * Susan Simmons-Alling, MSN, APRN, BC ABSTRACT This article focuses primarily on the pharmacologic strategies recommended for bipolar disorder.

More information

Decreasing the minimum length criterion for an episode of hypomania: evaluation using self-reported data from patients with bipolar disorder

Decreasing the minimum length criterion for an episode of hypomania: evaluation using self-reported data from patients with bipolar disorder Eur Arch Psychiatry Clin Neurosci (2011) 261:341 347 DOI 10.1007/s00406-010-0187-x ORIGINAL PAPER Decreasing the minimum length criterion for an episode of hypomania: evaluation using self-reported data

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Di Florio A, Forty L, Gordon-Smith K, Heron J, Jones L, Craddock N, Jones I. Perinatal episodes across the mood disorder spectrum. Arch Gen Psychiatry. Published online December

More information

ORIGINAL ARTICLE. The Effects of Adherence to Antidepressant Treatment Guidelines on Relapse and Recurrence of Depression

ORIGINAL ARTICLE. The Effects of Adherence to Antidepressant Treatment Guidelines on Relapse and Recurrence of Depression ORIGINAL ARTICLE The Effects of Adherence to Antidepressant Treatment Guidelines on Relapse and Recurrence of Depression Catherine A. Melfi, PhD; Anita J. Chawla, PhD; Thomas W. Croghan, MD; Mark P. Hanna,

More information

4/29/2016. Psychosis A final common pathway. Early Intervention in Psychotic Disorders: Necessary, Effective, and Overdue

4/29/2016. Psychosis A final common pathway. Early Intervention in Psychotic Disorders: Necessary, Effective, and Overdue Early Intervention in Psychotic Disorders: Necessary, Effective, and Overdue Disclosures Financial relationships with commercial interests Douglas R. Robbins, M.D. Maine Medical Center Tufts University

More information

CURRICULUM VITAE. David A. Solomon

CURRICULUM VITAE. David A. Solomon 3/24/06 CURRICULUM VITAE David A. Solomon Business Address: Department of Psychiatry, Jane Brown Five North Rhode Island Hospital 593 Eddy Street Providence, Rhode Island 02903-4970 Business Telephone

More information

Treatment of Bipolar disorder

Treatment of Bipolar disorder 8/6/215 Treatment of Bipolar disorder Pichai Ittasakul, M.D. Department of Psychiatry, Ramathibodi Hospital, Mahidol University Bipolar disorder Manic-depressive Illness. is characterized by the occurrence

More information

Bipolar disorders: treatment options and patient satisfaction

Bipolar disorders: treatment options and patient satisfaction REVIEW Bipolar disorders: treatment options and patient satisfaction Charles Bowden Vivek Singh Department of Psychiatry, The University of Texas Health Science Center at San Antonio, San Antonio, TX,

More information

1. Introduction Overview Organization of Executive Summary

1. Introduction Overview Organization of Executive Summary Executive Summary and Discussion of the Vagus Nerve Stimulation (VNS) Therapy Depression Indication Clinical Data (Updated to Include Information from Deficiency Letter Response) Prepared By: Richard L.

More information

Pharmacy Prior Authorization GMH/SA and Non-Title 19/21 SMI Non-Formulary and Prior Authorization Guidelines

Pharmacy Prior Authorization GMH/SA and Non-Title 19/21 SMI Non-Formulary and Prior Authorization Guidelines Non-Formulary Behavioral Health Medications ADHD medications for children under The patient must have a diagnosis for which the requested medication is: o Approved based on FDA indication and limits; OR

More information

Inadequacy of Antidepressant Treatment for Patients With Major Depression Who Are at Risk for Suicidal Behavior

Inadequacy of Antidepressant Treatment for Patients With Major Depression Who Are at Risk for Suicidal Behavior Inadequacy of Antidepressant Treatment for Patients With Major Depression Who Are at Risk for Suicidal Behavior Maria A. Oquendo, M.D., Kevin M. Malone, M.D., Steven P. Ellis, Ph.D., Harold A. Sackeim,

More information

Management of Bipolar Depression

Management of Bipolar Depression Management of Bipolar Depression Haresh M. Tharwani, M.D. Associate Clinical Professor Medical Director-DRH & Duke Psychiatry Specialty Clinic of Cary, N.C. Bipolar Disorders (Manic-Depressive illness)

More information

Adherence in A Schizophrenia:

Adherence in A Schizophrenia: Understanding and Diagnosing Bipolar Disorder Treatment Promoting for Bipolar Treatment Disorder Adherence in A Schizophrenia: Resource for Providers Engagement Strategies for Health Care Providers, Case

More information

5 COMMON QUESTIONS WHEN TREATING DEPRESSION

5 COMMON QUESTIONS WHEN TREATING DEPRESSION 5 COMMON QUESTIONS WHEN TREATING DEPRESSION Do Antidepressants Increase the Possibility of Suicide? Will I Accidentally Induce Mania if I Prescribe an SSRI? Are Depression Medications Safe and Effective

More information

Substance use and perceived symptom improvement among patients with bipolar disorder and substance dependence

Substance use and perceived symptom improvement among patients with bipolar disorder and substance dependence Journal of Affective Disorders 79 (2004) 279 283 Brief report Substance use and perceived symptom improvement among patients with bipolar disorder and substance dependence Roger D. Weiss a,b, *, Monika

More information

Continuum of depressive and manic mixed states in patients with bipolar disorder: quantitative measurement and clinical features

Continuum of depressive and manic mixed states in patients with bipolar disorder: quantitative measurement and clinical features RESEARCH REPORT Continuum of depressive and manic mixed states in patients with bipolar disorder: quantitative measurement and clinical features Al a n C. Sw a n n, Jo e l L. Steinberg, Marijn Lijffijt,

More information

Department of Psychiatry & Behavioral Sciences. University of Texas Medical Branch

Department of Psychiatry & Behavioral Sciences. University of Texas Medical Branch Depression in Childhood: Advances and Controversies in Treatment Karen Dineen Wagner, MD, PhD Marie B. Gale Centennial Professor & Vice Chair Department of Psychiatry & Behavioral Sciences Director, Division

More information

Suicide Risk and Melancholic Features of Major Depressive Disorder: A Diagnostic Imperative

Suicide Risk and Melancholic Features of Major Depressive Disorder: A Diagnostic Imperative Suicide Risk and Melancholic Features of Major Depressive Disorder: A Diagnostic Imperative Robert I. Simon, M.D.* Suicide risk is increased in patients with Major Depressive Disorder with Melancholic

More information

What Is the Mechanism by Which Suicide Attempts Predispose to Later Suicide Attempts? A Mathematical Model

What Is the Mechanism by Which Suicide Attempts Predispose to Later Suicide Attempts? A Mathematical Model Journal of Abnormal Psychology 989, Vol. 98, o.,-9 Copyright 989 by the American Psychological Association, Inc. l-8x/89/$.7 What Is the Mechanism by Which Suicide Attempts Predispose to Later Suicide

More information

Resubmission. Scottish Medicines Consortium

Resubmission. Scottish Medicines Consortium Scottish Medicines Consortium Resubmission aripiprazole 5mg, 10mg, 15mg, 0mg tablets; 10mg, 15mg orodispersible tablets; 1mg/mL oral solution (Abilify ) No. (498/08) Bristol-Myers Squibb Pharmaceuticals

More information

MARTIN B. KELLER, MD

MARTIN B. KELLER, MD MARTIN B. KELLER, MD Brown University/Butler Hospital 345 Blackstone Blvd, Providence, RI 02906 Professor Emeritus, Department of Psychiatry and Human Behavior Alpert Medical School, Brown University Chief,

More information

Obsessive-Compulsive Disorder Clinical Practice Guideline Summary for Primary Care

Obsessive-Compulsive Disorder Clinical Practice Guideline Summary for Primary Care Obsessive-Compulsive Disorder Clinical Practice Guideline Summary for Primary Care CLINICAL ASSESSMENT AND DIAGNOSIS (ADULTS) Obsessive-Compulsive Disorder (OCD) is categorized by recurrent obsessions,

More information

Lithium in bipolar disorders.

Lithium in bipolar disorders. Lithium in bipolar disorders. S. Mehdi Samimi Ardestani M.D. Department of Psychiatry, Shahid Beheshti University of Medical Science, Behavioral science research center Iranian psychiatric association,

More information

BIPOLAR DISORDER IS A MAJOR

BIPOLAR DISORDER IS A MAJOR ORIGINAL CONTRIBUTION Suicide Risk in Bipolar Disorder During Treatment With Lithium and Divalproex Frederick K. Goodwin, MD Bruce Fireman, MA Gregory E. Simon, MD Enid M. Hunkeler, MA Janelle Lee, MHA,

More information

2) Percentage of adult patients (aged 18 years or older) with a diagnosis of major depression or dysthymia and an

2) Percentage of adult patients (aged 18 years or older) with a diagnosis of major depression or dysthymia and an Quality ID #370 (NQF 0710): Depression Remission at Twelve Months National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Prevention, Treatment, and Management of Mental Health

More information

Outcome of Bipolar I (mania) disorders, In Relation with Personality Profile

Outcome of Bipolar I (mania) disorders, In Relation with Personality Profile APRIL 2008 DELHI PSYCHIATRY JOURNAL Vol. 11 No.1 Original Article Outcome of Bipolar I (mania) disorders, In Relation with Personality Profile L.N. Gupta, K.K. Verma, Shriniwas Department of Psychiatry,

More information

Diagnostic orphans for alcohol use disorders in a treatment-seeking psychiatric sample

Diagnostic orphans for alcohol use disorders in a treatment-seeking psychiatric sample Available online at www.sciencedirect.com Drug and Alcohol Dependence 96 (2008) 187 191 Short communication Diagnostic orphans for alcohol use disorders in a treatment-seeking psychiatric sample Lara A.

More information

A randomized controlled clinical trial of Citalopram versus Fluoxetine in children and adolescents with obsessive-compulsive disorder (OCD)

A randomized controlled clinical trial of Citalopram versus Fluoxetine in children and adolescents with obsessive-compulsive disorder (OCD) Eur Child Adolesc Psychiatry (2009) 18:131 135 DOI 10.1007/s00787-007-0634-z ORIGINAL CONTRIBUTION Javad Alaghband-Rad Mitra Hakimshooshtary A randomized controlled clinical trial of Citalopram versus

More information

Four-Year Longitudinal Course of Children and Adolescents With Bipolar Spectrum Disorders: The Course and Outcome of Bipolar Youth (COBY) Study

Four-Year Longitudinal Course of Children and Adolescents With Bipolar Spectrum Disorders: The Course and Outcome of Bipolar Youth (COBY) Study Article Four-Year Longitudinal Course of Children and Adolescents With Bipolar Spectrum Disorders: The Course and Outcome of Bipolar Youth (COBY) Study Boris Birmaher, M.D. David Axelson, M.D. Benjamin

More information

Therapeutic Drug Monitoring of Mood Stabilizers in Medicaid Patients With Bipolar Disorder

Therapeutic Drug Monitoring of Mood Stabilizers in Medicaid Patients With Bipolar Disorder Therapeutic Drug Monitoring of Mood Stabilizers in Medicaid Patients With Bipolar Disorder Steven C. Marcus, Ph.D., Mark Olfson, M.D., M.P.H., Harold A. Pincus, M.D., Deborah A. Zarin, M.D., and David

More information

Clinical Guideline for the Management of Bipolar Disorder in Adults

Clinical Guideline for the Management of Bipolar Disorder in Adults Clinical Guideline for the Management of Bipolar Disorder in Adults Goal: To improve the quality of life of adults with bipolar disorder Identification and Treatment of Bipolar Disorder Criteria for Diagnosis:

More information

Affective Disorders in the Age of Prozac. Robert Whitaker May 2016

Affective Disorders in the Age of Prozac. Robert Whitaker May 2016 Affective Disorders in the Age of Prozac Robert Whitaker May 2016 Depression in the Pre-Antidepressant Era Who It Affected Major depression was primarily a disorder of middle-aged and older persons. In

More information

DISEASES AND DISORDERS

DISEASES AND DISORDERS DISEASES AND DISORDERS 13. The mood (affective) disorders 99 14. The psychotic disorders: schizophrenia 105 15. The anxiety and somatoform disorders 111 16. Dementia and delirium 117 17. Alcohol and substance-related

More information

Study Guide Unit 3 Psych 2022, Fall 2003

Study Guide Unit 3 Psych 2022, Fall 2003 Psychological Disorders: General Study Guide Unit 3 Psych 2022, Fall 2003 1. What are psychological disorders? 2. What was the main treatment for some psychological disorders prior to the 1950 s? 3. What

More information

CASE 5 - Toy & Klamen CASE FILES: Psychiatry

CASE 5 - Toy & Klamen CASE FILES: Psychiatry CASE 5 - Toy & Klamen CASE FILES: Psychiatry A 14-year-old boy is brought to the emergency department after being found in the basement of his home by his parents during the middle of a school day. The

More information

A systematic review of the evidence on the treatment of rapid cycling bipolar disorder

A systematic review of the evidence on the treatment of rapid cycling bipolar disorder Bipolar Disorders 2013: 15: 115 137 Review Article Ó 2013 John Wiley and Sons A/S Published by Blackwell Publishing Ltd. BIPOLAR DISORDERS A systematic review of the evidence on the treatment of rapid

More information

Office Practice Coding Assistance - Overview

Office Practice Coding Assistance - Overview Office Practice Coding Assistance - Overview Three office coding assistance resources are provided in the STABLE Resource Toolkit. Depression & Bipolar Coding Reference: n Provides ICD9CM and DSM-IV-TR

More information

Complicated Case Histories Key Words: tricyclic antidepressants, bipolar, mania, susceptible, adverse effects

Complicated Case Histories Key Words: tricyclic antidepressants, bipolar, mania, susceptible, adverse effects Complicated Case Histories Key Words: tricyclic antidepressants, bipolar, mania, susceptible, adverse effects Induction of Psychosis by Cyclobenzaprine By Johan Y. Cohen, Amélie Guilbault ABSTRACT ~ Due

More information

Two-year stability and change of schizotypal, borderline, avoidant and obsessive-compulsive personality disorders

Two-year stability and change of schizotypal, borderline, avoidant and obsessive-compulsive personality disorders Wesleyan University WesScholar Division III Faculty Publications Natural Sciences and Mathematics October 2004 Two-year stability and change of schizotypal, borderline, avoidant and obsessive-compulsive

More information

The Diagnostic Stability of DSM-IV Diagnoses: An Examination of Major Depressive Disorder, Bipolar I Disorder, and Schizophrenia in Korean Patients

The Diagnostic Stability of DSM-IV Diagnoses: An Examination of Major Depressive Disorder, Bipolar I Disorder, and Schizophrenia in Korean Patients Original Article pissn 1738-1088 / eissn 2093-4327 Clinical Psychopharmacology and Neuroscience 2011;9(3):117-121 Copyrightc 2011, Korean College of Neuropsychopharmacology The Diagnostic Stability of

More information

Antidepressant Utilization in Bipolar Disorder: What Is the Evidence?

Antidepressant Utilization in Bipolar Disorder: What Is the Evidence? Antidepressant Utilization in Bipolar Disorder: What Is the Evidence? 2018 Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD Lundbeck, LLC March 2018 MRC2.CORP.D.00336 Today s

More information

Course and Outcome for Schizophrenia Versus Other Psychotic Patients: A Longitudinal Study

Course and Outcome for Schizophrenia Versus Other Psychotic Patients: A Longitudinal Study Course and Outcome for Schizophrenia Versus Other Psychotic Patients: A Longitudinal Study Abstract by Martin Harrow, James R. Sands, Marshall L. Silverstein, and Joseph F. Qoldberg We studied 276 patients

More information

Guilt Suicidality. Depression Co-Occurs with Medical Illness The rate of major depression among those with medical illness is significant.

Guilt Suicidality. Depression Co-Occurs with Medical Illness The rate of major depression among those with medical illness is significant. 1-800-PSYCH If you are obsessive-compulsive, dial 1 repeatedly If you are paranoid-delusional, dial 2 and wait, your call is being traced If you are schizophrenic, a little voice will tell you what number

More information

BIPOLAR DISORDERS DIAGNOSTIC AND TREATMENT ISSUES RICHARD RIES MD

BIPOLAR DISORDERS DIAGNOSTIC AND TREATMENT ISSUES RICHARD RIES MD Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences BIPOLAR DISORDERS DIAGNOSTIC AND TREATMENT ISSUES RICHARD RIES MD PROFESSOR DEPARTMENT OF PSYCHIATRY UNIVERSITY

More information

Adolescent depression

Adolescent depression Diagnostic skills can differentiate 40 VOL. 1, NO. 7 / JULY 2002 teen angst from psychopathology Ann Wagner, PhD Chief, Autism and Pervasive Developmental Disorders Intervention Research Program Benedetto

More information

Practice Parameter for the Assessment and Treatment of Children and Adolescents with Bipolar Disorder,

Practice Parameter for the Assessment and Treatment of Children and Adolescents with Bipolar Disorder, Practice Parameter for the Assessment and Treatment of Children and Adolescents with Bipolar Disorder, Journal of the Academy of Child and Adolescent Psychiatry, 1997 Primary Authors: Jon McClellan MD

More information

Features of bipolarity among unipolars

Features of bipolarity among unipolars Features of bipolarity among unipolars Joanna Rymaszewska, Andrzej Kiejna, Tomasz Hadryś, Aleksandra Suwalska, Dorota Łojko, Janusz K. Rybakowski Summary Aim, material and method: The aim of the study

More information

Polarity of the First Episode and Time to Diagnosis of Bipolar I Disorder

Polarity of the First Episode and Time to Diagnosis of Bipolar I Disorder online ML Comm 0ORIGINAL ARTICLE0 Psychiatry Invest 2009;6:96-101 Print ISSN 1738-3684 / On-line ISSN 1976-3026 Polarity of the First Episode and Time to Diagnosis of Bipolar I Disorder Boseok Cha 1 Jeong

More information

Hopelessness Predicts Suicide Ideation But Not Attempts: A 10-Year Longitudinal Study

Hopelessness Predicts Suicide Ideation But Not Attempts: A 10-Year Longitudinal Study Suicide and Life-Threatening Behavior 1 2017 The American Association of Suicidology DOI: 10.1111/sltb.12328 Hopelessness Predicts Suicide Ideation But Not Attempts: A 10-Year Longitudinal Study TIANYOU

More information

In order to prove the efficacy of a drug in treating major

In order to prove the efficacy of a drug in treating major Article Suicide Risk in -Controlled Studies Major Depression Jitschak G. Storosum, M.D. Barbara J. van Zwieten, Ph.D. Wim van den Brink, M.D., Ph.D. Berthold P.R. Gersons, M.D., Ph.D. André W. Broekmans,

More information

Bipolar disorder treatment research: new initiatives needed

Bipolar disorder treatment research: new initiatives needed INTERVIEW Bipolar disorder treatment research: new initiatives needed Robert M Post : Robert Post graduated from Yale University (CT, USA) in 1964, the University of Pennsylvania School of Medicine (PA,

More information

Depressive Disorder in Children and Adolescents: Dysthymic Disorder and the Use of Self-Rating Scales in Assessment

Depressive Disorder in Children and Adolescents: Dysthymic Disorder and the Use of Self-Rating Scales in Assessment Depressive Disorder in Children and Adolescents: Dysthymic Disorder and the Use of Self-Rating Scales in Assessment Stuart Fine, MB, FRCP (C), Marlene Moretti, MA, Glenn Haley, MA, Simon Fraser University.

More information